Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?Zacks Investment Research · 2 days ago
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin DeficiencyGlobeNewsWire · 3 days ago
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 16, 2026
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121GlobeNewsWire · Oct 5, 2026
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of “Moderate Buy” by BrokeragesDefense World · Sep 21, 2026
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 11, 2026Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.34 | -$1.07 | Beat |
| May 7, 2026 | -$1.60 | -$1.69 | Miss |
| Mar 12, 2026 | -$1.93 | -$5.32 | Miss |
| Nov 12, 2025 | -$2.61 | -$1.92 | Beat |
| Aug 12, 2025 | -$2.54 | -$2.74 | Miss |
| May 7, 2025 | -$2.60 | -$2.49 | Beat |